{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"In the Interim...","title":"The SNAP Trial with Professors Tong and Davis","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/3fb026e2\"></iframe>","width":"100%","height":180,"duration":3233,"description":"In this episode of \"In the Interim…\", Dr. Scott Berry interviews Professors Steven Tong and Josh Davis about the SNAP platform trial for Staphylococcus aureus bacteremia. The discussion covers SNAP’s rationale, large-scale adaptive design, methodology, and operational execution at approximately 150 hospitals in 13 countries. Key statistical questions, domain results, pediatric-adult analysis, and global implementation strategy are explored in depth. Listeners will find clear examples of how adaptive platform trials can efficiently address clinically relevant questions in infectious disease, while highlighting the nuances of trial design, statistical thresholds, and network collaboration.\nKey Highlights\nHigh and unchanging mortality for Staphylococcus aureus bacteremia—over one million deaths annually.\nSNAP leverages silo-based structure (MSSA, MRSA, PSSA) and factorial domains for simultaneous, efficient investigation of treatments.\nCefazolin shown non-inferior to flucloxacillin for MSSA with lower related acute kidney injury.\nIn PSSA, penicillin demonstrated significantly less toxicity and favorable mortality signal over flucloxacillin; mortality difference did not meet the statistical superiority threshold.\nFutility reached in the adjunctive clindamycin domain for effect on 90-day mortality.\nBoth adults and children enrolled, with pediatric results using statistical borrowing from adults in line with FDA Bayesian guidance.\nOngoing platform expansion includes bacteriophage therapy, antiplatelet domains, and evaluation of diagnostic strategies.\nStatistical leadership: Dr. Anna McGlothlin (Berry Consultants), Dr. Julie Marsh (statistics lead).\nFor more, visit us at https://www.berryconsultants.com/","thumbnail_url":"https://img.transistorcdn.com/toFATB0JXvqQXRqzUqrK1EWCJCLOA_Qvjkb5ml3q-s8/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9jM2M0/ZDE2YzA1N2FhNjkx/NDk1NDczNjYzM2E5/NjlmYS5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}